Skip to main content

Table 3 The relation of poor clinical and pathological response to the clinico-pathological variables.

From: CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer

  Poor clinical Response p value Poor pathological Response p value
Tumour size     
   <2.5 cm 1/29(3.4%)   5/45(11%)  
   >2.5 cm 28/29(96.5%) 0.052 40/45(88.8%) 0.001
Tumour Histology     
   Ductal 26/29(89.6%) 0.216 40/45(74%) 0.187
   Lobular 1/29(3.4%)   2/45(3.7%)  
   Mixed 2/29(6.8%)   3/45(5.5%)  
Tumour stage     
   II 2/29(6.8%)   8/45(17.7%) 0.26
   III 24/29(82.7%) 0.014 37/45(82.2%) 0.26
   IV 3/29(10.3%)   Non  
Her2/neu positive 8/29(27.5%) 0.410 8/45(17.7%) 0.666
ER positive 18/29(62.1%) 0.396 32/45(91.4) 0.052
LVI 13/29(44.8%) 0.141 23/45(51.1%) 0.034
CA 15-3 before PC 13/29(50%) 0.013 17/45(37.7%) 0.044
CA 15-3 after PC 14/29(46.2%) 0.012 16/45(35.5%) 0.045
  1. Fisher's exact test was used for categorical variables and Wilcoxon's test for continuous variables. A P-value of less than 0.05 was considered to be significant. LVI (lympho-vascular space invasion) and PC (primary chemotherapy).